{"id":"benzalamide","rwe":[],"tags":[{"label":"benzalamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"lipobeta","offLabel":[],"synonyms":["benzalamide","beta-benzalbutyramide","lipidemol","lipobeta","3-Methyl-4-phenyl-3-butenamide"],"timeline":[],"brandName":"Lipobeta","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"benzalamide","explanation":"Imagine your body's cells have locks on them, and Lipobeta is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock open or closed, depending on the type of lock and the key's shape. This can affect how the cell behaves and responds to signals.","oneSentence":"Lipobeta is thought to work by interacting with a specific target in the body, although the exact mechanism is not yet understood.","technicalDetail":"Lipobeta is a small molecule that binds to a specific protein target, potentially modulating its activity and influencing downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3682","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=benzalamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:58:42.592614","biosimilars":[],"competitors":[],"genericName":"benzalamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"500AC5XYXO","CHEBI":"CHEBI:134810","UMLSCUI":"C0615544","PUBCHEM_CID":"23660","MESH_SUPPLEMENTAL_RECORD_UI":"C033391"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Lipobeta, also known as benzalamide, is a small molecule drug in the benzalamide class. Its target and exact mechanism of action are unknown, but it is being developed for potential therapeutic applications. The commercial status of Lipobeta is unclear, and it has not been approved by the FDA for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and approved indications are currently unavailable.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}